21 CFR Part 11 & AI — What Your Tools Must Guarantee

Why 21 CFR Part 11 also applies to AI

21 CFR Part 11 defines the criteria under which electronic records and electronic signatures can be considered trustworthy, reliable, and equivalent to paper records. When AI is used within a regulated clinical workflow, it becomes part of the validated application landscape and quality system.

In other words, an AI tool used to produce or transform content with regulatory impact cannot be treated like a simple office productivity assistant. If it influences trial data, submitted documents, quality review activities, or documented operational decisions, it enters a scope that requires validation, access control, traceability, and change governance.

1. Formal system validation

Any system used in a regulated environment must be validated to demonstrate that it performs as intended in a consistent and reliable manner. For AI tools, this means documenting intended uses, functional requirements, performance testing, known limitations, and revalidation triggers whenever the model or its configuration changes.

2. Complete and tamper-evident audit trail

The regulation requires secure, computer-generated, time-stamped audit trails that record the creation, modification, and deletion of records, together with the identity of the person performing the action. In an AI setting, this should also extend to prompts, relevant inputs, generated outputs, model versions, and associated human review actions.

3. Access controls and security

Systems compliant with 21 CFR Part 11 must implement appropriate access controls, including unique user IDs, robust authentication, and permission management aligned with user roles. For AI tools, this should also include data encryption, environment segregation, and strict partitioning across studies, sponsors, or teams where required.

4. Data integrity, retention and retrieval

Compliance also requires records to remain complete, readable, protected against alteration, and retrievable for the full applicable retention period. For AI tools, this means structured retention of prompts, outputs, source documents, and technical logs needed to justify how a result was produced.

5. Compliant electronic signatures

Part 11 also governs electronic signatures, which must be uniquely linked to an individual, supported by appropriate authentication controls, and permanently associated with the signed record. When AI is part of an approval workflow, it must integrate with a compliant review and signature process rather than bypass it.

Concrete AI use cases in clinical research

• AI suggesting responses to data queries in the EDC, with final approval by the data manager and full traceability of the suggestion and decision.
• AI assisting with automated eTMF document classification, with an audit trail showing both the model suggestion and the final user decision.
• AI pre-drafting pharmacovigilance narratives or sections of clinical documents, subject to mandatory human review before formal approval.
• AI summarizing monitoring notes or pre-classifying protocol deviations, provided that model versions, validation rules, and usage boundaries are properly documented.

What to require from vendors

Sponsors, CROs, and quality teams should request clear documentation covering architecture, security, validation, logging, change control, and model governance. A vendor that cannot explain how logs are protected, how model versions are controlled, or how data is segregated presents a clear risk for regulated use.